> ## Content Index
> Fetch the complete content index at: https://www.biostockinfo.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIOTECH CATALYST AI SCANNER — October WK1
- URL: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-october-wk1/
- Published: 2026-09-27T14:59:58.000Z
- Updated: 2026-09-27T15:03:16.000Z
- Author: Alex

I’ve been travelling for over a week, with the calendar running autonomously while I’ve been away. I managed to put together the October Week 1 Scanner remotely, but haven’t been able to personally cross-check every detail before publication. Please verify key information against the original sources. Thank you for your understanding.

BIOSTOCKINFO / CATALYST SCANNER

Scan date 2026-09-27 · 10 featured · 10 watchlist

## The tape

The SPDR S&P Biotech ETF (XBI) closed September 25 at 155.03, falling 1.1% over one week, 7.9% over one month, and 0.2% over three months, while remaining up 27.6% year to date and 8.6% below its 52-week high of 169.55\. In contrast, the S&P 500 ETF (SPY) closed at 771.35, gaining 1.3% over one week, 0.7% over one month, 5.8% over three months, and 12.9% year to date, sitting 0.8% below its 52-week high of 777.88\. This divergence indicates that current weakness is sector-specific rather than market-wide.

Across the broader tracked US equity universe, 30% of 5,826 names closed above their 20-day moving average. This breadth measure is not specific to biotech and should be read alongside the XBI/SPY comparison.

The US 10-year Treasury yield closed at 5.18% on September 25, rising 19 basis points over one week and 81 basis points across three months to reach its 52-week high.

## This week at a glance

| TICKER            | CATALYST                                                    | DATE                | RANK |
| ----------------- | ----------------------------------------------------------- | ------------------- | ---- |
| [**NRXP**](#NRXP) | GDUFA, ketamine                                             | Nov 10, 2026        | 86   |
| [**KYTX**](#KYTX) | Conference Presentation, miv-cel (mivocabtagene autoleucel) | Oct 21–Oct 23, 2026 | 82   |
| [**AGIO**](#AGIO) | PDUFA, PYRUKYND (mitapivat)                                 | Nov 1, 2026         | 82   |
| [**IRD**](#IRD)   | PDUFA, Phentolamine Ophthalmic Solution 0.75%               | Oct 17, 2026        | 81   |
| [**IONS**](#IONS) | PDUFA, bepirovirsen                                         | Oct 26, 2026        | 81   |
| [**RAPP**](#RAPP) | Topline Data, RAP-219                                       | October 2026        | 80   |
| [**BNTC**](#BNTC) | Conference Presentation, BB-301                             | Oct 27–Oct 30, 2026 | 80   |
| [**INO**](#INO)   | PDUFA, INO-3107                                             | Oct 30, 2026        | 80   |
| [**PALI**](#PALI) | Conference Presentation, PALI-2108                          | Oct 17–Oct 20, 2026 | 80   |
| [**BMEA**](#BMEA) | Topline Data, BMF-650                                       | October 2026        | 79   |

Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.

## Featured

### NRXP — NRx Pharmaceuticals

| CATALYST**Nov 10, 2026**Regulatory | RANK**86**          | PRICE**$3.00**\-17% 20d |
| ---------------------------------- | ------------------- | ----------------------- |
| CAP**$130M**(43M sh)               | CASH**$43M**\~26 mo |                         |

**The FDA Office of Generic Drugs reviews the Abbreviated New Drug Application for preservative-free ketamine (NRX-100) with a Generic Drug User Fee Amendments goal date of Nov 10, 2026.** The regulatory decision determines whether the company can commence commercial distribution of its intravenous formulation.

**Company.** NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders. It generates no commercial product revenue. Beyond preservative-free ketamine, the pipeline includes NRX-101 in Phase 3 and preclinical GNK-301.

**Science & competition.** NRX-100 is a preservative-free intravenous formulation of ketamine, an NMDA receptor antagonist. The selected catalyst is its generic-drug application. NRx’s separate psychiatric development programmes and their clinical results should not be treated as evidence of approval for this application.

Competition sources

Sources: [pharmacytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIPInXnbixQBuRzJAf5HG8Yg0FVc2LNhahm2TN6HGiIok06muxYGREXtKSWCBKLX--CMlGy8cZlhqPqeVngUrjpHKiFffI1sM6%5FBWPvToBTvW1eO3mENoRtgmH8NUkVLPZM2Q-MyF5EXYkE4TfMiJpta9%5FuqBkPQs8pQfuyr%5F9ytep8zi7l32j5szrPpVDzi31Dws5-uRJVUjedsUKjw0zkkNiEtuDyZxSaac=?ref=biostockinfo.com) · [drugs.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHaLpmwJd3YmPoe4dAaROlXI7FXX8rFEuw0is8juxVCqgA2E5oNXaQ8ZIERWJZnroweZONoSM7uYgIpo60st-YewiXQ6s1DzlSn9xfaQs7Aq-nhUhqYPHd-AYl3ZhbqU9No2SCtdg==?ref=biostockinfo.com) · [jnj.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH%5F8z4nw5Ep0plxhrXIvm%5Fcbim34ec0fQOHRZ9oNM4YFZtkZ1QwH0HRwZL6uunvfImLv2vCgtwWupz9yk8JHWiF29KB3c-7PJqIregSNg4ppME0p2eFubyqEYz6E%5FD3%5FW1d6NQ6xGUM57R5QgnH4ABxdZMBgNrJN9PD0lsL5-0a1JwZ8L1d6WtYtBV%5FASugXNTdSXWCsCWrC8HiLvHhoXPmrg2HrJ%5FSqr00vCGyIcI7uNzYm75wsU57GTLSN2u8UEYiVex4hNrZ1EAjZhaj0STA7LgoMW3nrqLDpstWUn3fKj4VtmGj4OFFCRksULL3qhiUu54nS1WBLmkWhtnONMIDrOtKZtWP9uvznJgI0yPx%5F9fB3zMNnB8Ijp-wFej6v6Crglpx?ref=biostockinfo.com) · [psychiatrictimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpUIlrieAjmwpq556nBoX56JpfMZhjJr0Ya-l8N6YLDu007BJOUhGMFvsSQ2EGePsNt0AKW8Rn88%5FIUxjFPvWnDiJ3hTxKlrEDn%5FxPGfBxzRtoO39ouIwQZD%5F5ZAYKlGMAzl4jjEUgH4OFFeOZIiskA18gVshTKPPbdWPj7zHRhVEnzpq9dYS%5FvYbHL2n3ExAAB7-ObUKrvEgIu5TN5MOav-UB?ref=biostockinfo.com) · [uic.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFY29DyTvh1UhdkGXSGwQbuCYK15oqe8EwoFovYT5cLBSfHgDH2MpVkvHsMe9H45j1BEAGIwrRwIosGvpzwiTKlqB8pZ7xWqyZDRgBfimAJxTKMd2r6s%5FTFczlUyI0kRflIzf41eXDMV2s5hOQb9rjKYvvtiBEk35Mj7Ju9hhQU6fd3pLnTLWXEY04NoIoFsW4v45A03KxNmztX9ROtQEXq11Fw78Xdk2mfhN4ekSCC6oGA99TazH8Ys047GRj9NgRgc46dIh64IUIlhgJXi2nzdU-pDlJqbv59kLmgWv%5FYOGD%5FMO3kNvy34jv2fDLl9fy%5F9kfD9C5WWIIg3Q==?ref=biostockinfo.com) · [nrxpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEI6pzkE-0tdyMs-Zn6ciOqQ4GvoE0TVsy3UHkmaxiYKmpeIr1P2O3Js3IY7J6KtQItyfLMk87x30XtI-%5FCjYV067rDDEJ8CA%5F91kBQ4vLD5yT9kNuV78rR6ls%5FVwFWPgd4pHj8kDrWNRuBZvDz33JWtW7Tud1AEximV1Kn8-mM2QyttJj-xwS%5FgSbeStl7HDHGPyd2a8S%5FiCzrXYJTjoT6rV-rnYZJR2HQEFUu1jmGBw0YJatKaJ7Wnd01bUhYNuejT2wciasm973g5Sg2pauk-WZWZ8FtcBeveScMk3TBms8=?ref=biostockinfo.com) · [fiercebiotech.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEZdtsEAN-wh-2vNybSkycxZ%5FtLHn0TMooqqRzW6VaSALBIVJWCsHFowjvECnMag06X6zLD3NC37te3%5FQuKL8JbA-aqoP6JAj1HS9AMnAmi0kB6MD%5FSGMD2nTTMQ8O7uNe5jwVPS%5F0uZ3j-pQtUJ5EXziyJSBB2-D5auRN0leq-kdiXDgQIQbqcPqr7NLXC3RunX5-nWqHCc38JFpseNJ2pmzD0i-u3KNFJRkUBpyerAocsMarJiPU9?ref=biostockinfo.com) · [psychiatrist.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE3vMpAc4khE8Q1db8p7QCxLUahBvJ4EJam1mRMBhYnuE4W7ZnHZXDc2stIS%5FUxS7uOYrD5QZyfJBJ9XmuXJrqOEYvJHAKVHESlbcVM59f1uix5iL0ktlJDvXBfcbmWMlJTcKBlOzN27sG6o1a1lQmjH-3AstHtcen%5FRV0ZA3cOVrpAVE7MD829MsTns3NGXErnxKModeiG%5FJo=?ref=biostockinfo.com)

**Why it could work.** The FDA reclassified the application amendment from major to minor and brought the goal date forward. That is a concrete procedural advance, although approval remains subject to review.

**Why it could fail.** Manufacturing or other application deficiencies could delay a decision. Even an approval would leave commercial execution and competition to be addressed.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=NRXP&ref=biostockinfo.com)

### KYTX — Kyverna Therapeutics

| CATALYST**Oct 21–Oct 23, 2026**Conference | RANK**82**           | PRICE**$6.81**\-21% 20d |
| ----------------------------------------- | -------------------- | ----------------------- |
| CAP**$421M**(62M sh)                      | CASH**$161M**\~12 mo |                         |

**Kyverna presents full 12-month data from the KYSA-8 registrational trial of miv-cel in stiff person syndrome at MS Toronto between Oct 21–Oct 23, 2026.** The presentation will give more detail on durability and safety ahead of the planned rolling Biologics License Application.

**Company.** Kyverna Therapeutics is a late-stage clinical immunology company developing cell therapies for autoimmune conditions. It has no approved commercial products. Other pipeline programs include miv-cel for generalized myasthenia gravis and progressive multiple sclerosis.

**Science & competition.** Miv-cel is an autologous chimeric antigen receptor T-cell therapy targeting CD19 to deplete pathogenic antibody-producing B-cells driving muscle spasms. Rivals include Qivigy (Kedrion Biopharma, Phase 3). Standard of care relies on high-dose gamma-aminobutyric acid agents combined with off-label intravenous immunoglobulin.

Competition sources

Sources: [practicalneurology.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtobGT0NCJNOInhAGPwIvga%5FBQzTquBfmwl92bcc0YDImPpWLVRCauZ8cHZHWWLlr5JLiWowA0FNpBWOGQ4QcIF6T2nXn4-%5Fch%5FIcRRxOPfS1rCCUlqAJrVRnQPpgpqB0riFAkpz8tnzLrNVMBLe-OnnN3NQTJy728qEpxDHplyVUUVzUD4OWRPmxdOZKEzVNZniPFB7ZxQv59Se7zh1jWna-CFTTFrAX31RUgnuzT9vXb%5Fh7QcYm48MM=?ref=biostockinfo.com) · [prnewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE4gQMJ5oBbhRjdv46n2aP0Y3zpOx8dIgS9C%5FnpDTNSPRkS8QJ9ndRfWm9FpkLTYM1pv%5FkYApkXmDQ%5FgVgGWCwq9Vgi6CsFiUBDOYG3%5F81MeYJfRe3YLuO3YKz4yQSXnE7Sh%5F3eFlOQpv8yDu9nTpia8tym3Of2czIQj9xNOe5DxJqEfg%5FPljU26xHte493Nk%5FqtkY%5FcapBRNmXVy8WKrtujz-svdcNjHcF3Y5ERVt4-5KdlCDXFrOwyMTyjqoVhet83PNw1Ym1oYuHaUzS%5FV3iuwxVmiUzzl5Z5b-XhFLmshik%5FMcs%5FQQ=?ref=biostockinfo.com) · [clinicaltrialsarena.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE-Z5vk37lLzpb4PjJoumpz5ffHmPsEbh7UeK47q-wejw6ndYOJIwGz8WLCwCHYxDOT3gy6Oa2eMtMGzVsfoI06P4tevNfdLnmCaEDvojbcnUOZuM1rSrBtGoafIkSMbX-2jYrag2O20qN08q-ORKLaGBJBCcComGROr8MCHRzuLmscG5y5uT07RNYOtJqRVVQ0CLocCD2gLaEsQtF%5FXn7X7II1?ref=biostockinfo.com) · [patsnap.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEzdUj1m-ZFbwLYqmrcVFij995oRZMVXWPmoIt4l%5FMagQE7V5j69VBfbLWYyqmYfC9vxBtbX1QE7EXf6P5gwI3mtNVXfX4tYO6gKjwiUQvJ8UNB5QT5fD8wEL11PqSZxp89b%5FztlyehNuiNe5XWosFCpvqUnnrGYcNW0mPtlkv-svWAxFU8JkTxzBnqYGs2Fn0lGzVxJSD9rRL-3QZ7?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDGfJKrT59w2HLwCumHMV6hsKp6NCdVI1O8TbynvZQLNkbxaE8Mb79yGknbrf98551v8yly3NQkBmk%5FkTCy1RZxV9sJO9wFlV70tI2MyDtNz3Jrtztd3fQ48n2AKAozg5gs6LN26A%5F?ref=biostockinfo.com) · [pharmaphorum.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEZ%5F%5FPiDSj5Z9gPw0A-Qelzf%5FoFnxpcEqzF4maQQolrU7HX8jx6o%5FD-Iibmfk4%5FzQNrqbQi7Yg1yXQM48pAc56IBvHEAzVTnW5uQTJQzaMLckfGtKPkHmfbyxqpegJLcc%5FdgxGnwbOxMPKFKSJTehYmkihO6Oa4ISypZDaDQujFlusU0eePM5t%5F?ref=biostockinfo.com) · [kyvernatx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXFIPnN6jvGuNnWoR2u4-CK6NY%5FAu8g54Twph4j2FpZVfRbIYi%5F7Q83XIC1Xkie85bEQp-57%5F7t3Dw9yZ6OsStNOMJh%5FCtFvxRFSYnNscaI29ilivrsLvbfstuomJGOXOlw4LEexOJZ8uRhI5dDzBccmbnUtfu3YUs86bju8Xa88bvOUEEIOmLRFZTNL0MKI0N2%5FzN-pTepSI6yeCN2rSb6MbPZMcNkqhFYA==?ref=biostockinfo.com) · [stiffperson.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFlorxwltQ-ESm%5FPBm9MZdl72b624DaegqAIaHu%5F5HdpaWwlpARWi-Y4Uw8iVst%5FwkpGv-ViwPuA6fru9c4UFE30tBEUeomR8KY68H7XxQyEyBngA4GEOljqFRPnUO1gNGkKDRnPG-%5F4txvR8tOITSZcVhu1WdGBJJ5lBmVxtflwdEAkWo4%5FJc=?ref=biostockinfo.com)

**Why it could work.** The company reported a sustained median 49% improvement on the timed walking test at 12 months, with 95% of patients maintaining clinically meaningful improvements. The fuller presentation should clarify those results.

**Why it could fail.** Neurologists may hesitate to prescribe autologous cell therapy if delayed neurotoxicity emerges, or if conditioning chemotherapy burdens and specialized cell handling cause substantial commercial resistance.

**Recent development.** On September 24, 2026, Kyverna announced positive 12-month topline durability data from KYSA-8 and longer-term generalized myasthenia gravis follow-up supporting a rolling BLA submission ([stocktitan.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE70A5OXyqEDQSCitjLQEyEA23dYpS%5Fz7UOo4nor4OGNCQAJyEdyJRd0jj-nJvycF93yzXeqp3S%5FJ1dQsRp7VM5HnOKYVuU5TqbVE%5FlrMpi2Idv57Gzy2eUoiq9RFHZtN0mhj-nPAYgCZ3GhBbe6TVZ2QjgFFaMIbTH2INoNYp3dUi-Jql81uaaGDoCRSeP5ZTeQjat5l0Xq2KHF0-3XaL1sgdVYlXSDek0MTAY?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=KYTX&ref=biostockinfo.com)

### AGIO — Agios Pharmaceuticals

| CATALYST**Nov 1, 2026**Regulatory | RANK**82**           | PRICE**$32.58**\-5% 20d |
| --------------------------------- | -------------------- | ----------------------- |
| CAP**$1.9B**(60M sh)              | CASH**$912M**\~30 mo |                         |

Filing warning

**The FDA decides on the supplemental New Drug Application for PYRUKYND in sickle cell disease under accelerated approval on Nov 1, 2026.** The decision concerns a potential additional indication for its commercial oral medicine.

**Company.** Agios Pharmaceuticals is a commercial-stage biopharmaceutical company marketing mitapivat for pyruvate kinase deficiency and thalassemia. The broader pipeline features AG-181 in phenylketonuria, AG-236 in polycythemia vera, and licensed cevidoplenib in immune thrombocytopenia.

**Science & competition.** Mitapivat is an oral small-molecule activator of pyruvate kinase that restores red blood cell energy metabolism to diminish sickling and hemolysis. Rivals include Hydroxyurea (Bristol Myers Squibb / Addmedica, Approved), Endari (Emmaus Medical, Approved), Adakveo (Novartis, Approved), Casgevy (Vertex Pharmaceuticals / CRISPR Therapeutics, Approved), Lyfgenia (bluebird bio, Approved), and Etavopivat (Novo Nordisk, Phase 3). Standard of care is hydroxyurea with chronic transfusions and supportive hydration.

Competition sources

Sources: [ucsf.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEu8Uv9NB9rpXdqxtVJNveihZ4qqWwkmirCBpc2EQOV1W%5F5vepRucG3osiPgRf0BbuqLFBebznwULeDSFjffPboxeVh8XqQ1-ByzyRa%5F6MBWloO2zOohqoSB5S4Mrzte9KbCUC1PWmUKdh43C4=?ref=biostockinfo.com) · [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrdMq9-bYna5D0Opxceh2eeWYdfloxGCpBI8C1bmyvskgBdlwoNqWgSfnHcRxXGN5OMFrCjWlTTbvDxv9Y-pHO47wjkC2nanerNCSQRzWulk0IqX2xWxkuBXrLbpB0Z6bcaY-WVmHp7TVDA0U1%5FaH6%5FW5W%5FcFmG6Rqpc-ujfMxzvfy3scG8kjXT17bFpa2hLvGxaigFhrTNx7Db8m6oGnhCM4ur2IIgoUasbhbYXVy8Vej8SUzY4d1F3bbSO7fFFVj4x4B87lfnSIDCmQnjuBicw==?ref=biostockinfo.com) · [thalassaemia.org.cy](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFMybH5G-ND16ujS-zVRdU4Gzg1bf3e3bJH1L1U0tdfhXq1P7iURALYWu5iFZyGCNsF7SvenKZOyGUYrmZNMn7R7dQKFXU%5FQqRyOrpRutpxU8unUXgqB5AQRL7LvvxI6ivkEx3ShnjpYYfCt7Rk2OSG3DomUDbRBzvCx0w=?ref=biostockinfo.com) · [molinamarketplace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvuSTr8LPgm8h3ZcJw6fZ07L9kgrY3g5yF3Q5W0QQbKLkt39eK-ps1BW%5FFHwO%5FyyUMULA3CeBgDk-wZQAjY-6Juyx9htunKXtNTSM92VcxIj5xj-ABrZsvXYVpHtFkKFfR7odcgVK2ULvMQgLonVee5sv%5FyDdYspGbKhAcLgXav11r18GLvViI5PcctL2M4LjwLZBh%5FQsUTwY%5FhxMp6TIR95L8EPFIDAvT?ref=biostockinfo.com) · [trialx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG1k8mM1xXyv1RgwA7fVuPUmLDe3Nomfaa7WPOOTqhpKy0nwhkGqi2WNqU607pCwJgRCAmh3gCOitf-VY3UTFfxxpaYT%5FL1xxNzYAI3jTKap3%5FMxdrnjFOolOUtyDkuu0ukcGrqx3DOyv8UaEYrG%5FOHbozlXKuiEpLkkqcoJf4-ObijMiWIY98kSr%5Fydv-aaJJjAlo=?ref=biostockinfo.com) · [caremark.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHewRJQdb6c4SvE-%5Fj%5FPcRVSoQxnSQwbLWHIA2e4gXi6ZTlgrJoT7WK7u6GTH6-HYiv2ab1EJIqNAEJ5xN9up0UOFurUlXNMgfEZbgmiOJBZUMFcCoMVdXebhQYQgMLC5iS6zkNgDxvBQ2sFfJ42ILuGuq998jNicrxYC7hJZdbwOcRtFFh4OM3x53acSdDoMDW4pPgFIxPh8iT0zxTl5COkKO--UOIA4OF2Mq2I0bq3tPgVXpa?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF%5F8mowZupAo%5FK4mg6S0rUGAo0WUzuAWVLajY-4uMLXvq%5FkNbhETUJi5SbcWBIV4J9OT2OgjLnut1KaavcxYXC7pcNuKDPLreW3p%5FLPZ%5FM0CNjTQ6jN-gMrMD7%5FIpAVysVZGRHCr%5Fhpd%5FHYwvLEIQrz3KqGf1KPU2HUUZ9lWl6swfk%5FACi0h05a?ref=biostockinfo.com) · [oncodaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH2Ck-weS71eodP6bpwVQCehDgjCZFcQEX5kYOGa2BZW84s9YYBKUAb8LtzZf1yWABgcVbGaX8lRypkTTVedYgr%5FpF7fsQNKU7gu8JSmgMKkElsuUCTOVG59sGgtYLLu3hio0jtKDhMIV5wEgBPTg6szNn%5F4hAQDOHRZUhXr4goDq7tU80=?ref=biostockinfo.com)

**Why it could work.** Mitapivat is already commercialized in other blood disorders. Phase 3 RISE UP results support the sickle-cell submission; the FDA’s review will determine whether that evidence supports the requested indication.

**Why it could fail.** The FDA may demand validated reductions in vaso-occlusive crisis rates from the ongoing confirmatory Phase 3 REIGNITE trial rather than approving based solely on surrogate hemoglobin levels.

**Filing flag.** Agios announced that it will not advance tebapivat in lower-risk myelodysplastic syndromes (LR-MDS) or sickle cell disease following Phase 2b and Phase 2 trial results, as it did not meet predefined thresholds for advancement or show a sufficiently differentiated profile.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AGIO&ref=biostockinfo.com)

### IRD — Opus Genetics

| CATALYST**Oct 17, 2026**Regulatory | RANK**81**          | PRICE**$4.76**+24% 20d |
| ---------------------------------- | ------------------- | ---------------------- |
| CAP**$396M**(83M sh)               | CASH**$79M**\~23 mo |                        |

**The FDA reviews the supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% in presbyopia with a PDUFA action date of Oct 17, 2026.** The decision determines whether the company commercializes an eye drop for near-vision loss.

**Company.** Opus Genetics is a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases. Its internal pipeline includes preclinical and clinical gene therapy candidates OPGx-BEST1, OPGx-LCA5, OPGx-RDH12, and OPGx-MERTK.

**Science & competition.** Phentolamine ophthalmic solution is an alpha-adrenergic antagonist that selectively relaxes the iris dilator muscle to narrow the pupil without inducing ciliary muscle spasm. Rivals include Vuity (AbbVie / Allergan, FDA-approved), Qlosi (Orasis Pharmaceuticals, FDA-approved), Vizz (LENZ Therapeutics, FDA-approved), Yuvezzi / Brimochol PF (Tenpoint Therapeutics, FDA-approved), and MicroLine (Eyenovia, Phase 3). The standard of care is corrective eyewear including reading glasses and multifocal lenses.

Competition sources

Sources: [ophthalmologytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjxk6cLSHTWwiaEtVZ41HchEKp4wQyA11eyNK1EWXmOZC5CvBRAJb8CsWNUgv6BGUnnA7cOCs2wrm8GaQB2Pbij%5F%5FSRtBHlkf5hF3AW6SBWA4fja%5Fcw5YA5WGpzvxTBCZREosCiUB0TiQCoMCYSltbpAmWLsEZYoxThu47C9nN3hIt6ZTtSxcdu%5FHRkNiDJg-1txHsVSYgPtV63AWm?ref=biostockinfo.com) · [medcitynews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYEGvh4zYpSe6aBjONkHRzImaWCQiWLqln8irFxT0HgP7VYdcMLbUNZmxGYsraE4RJ4rbU4TZppV0AwzElv8QAB%5FzHFfIHB7hUxgemdYm5IZ7UdFg0yXkw6kI9EIfEzY3W8aCxyegDWfkl8rhXRLrn99-UCY7t2T3RAoXANnnaRABVHLtfk9gQMCD-wxX1H%5FqPoGgjUygfY9cmd-vVRMON378GV7ANwMH2ymc=?ref=biostockinfo.com) · [ophthalmologymanagement.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFknBHvU29H8OrgUmT7nur83hWDk96L00Wm4ZoWB9x%5F40LD%5FZh%5FYhdm1fKmsLlwK6PEZHQRGlfh836y0fuhJ%5FiDVFK8ZxlgJegvBsbyOHMujXXrMMHDI4w5DcYmf4eytgWU3wzrdWAdYbrWcaP69eiBTK0YzyP55cyMwRHPwnefFOOOPgI2VJI8lV8gCpin%5F28=?ref=biostockinfo.com) · [presbyopiaphysician.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFTLpcekrA9CH2ld14PJTRjKCzdMDAozaJIEIt0HEDBT7mGRBnYUJnGVpDqjHBkeSC7rcw%5Fggwc56Ejl2kEKtptwMlrbdL5PY0LMR96oXX9R1jPWZonMqgqd9Kxeg6J4aLV9iw5apZIw8HTZsYfnpwU%5FHB1Rgj4sEkLEOcRGVAy05-VM2ib4NeBcwNy57AN?ref=biostockinfo.com) · [reviewofophthalmology.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFSxEuLelFAFuiAZMoza24cxfCv7rEeiF9mXiUlNA9R%5FyyEIZT-86DvONnDl0cU1qGIGd56a2EYs8K64ZlvQ575heQBF15YOX9TxtdbufQwPH5OkDnwqARxZJcD2Kn3GyTheV9iJkerI1Ymp8OAy9FLH9vgs6AuV7dxUswCNWdWUilNjOfs?ref=biostockinfo.com) · [optometrytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGitmJZWEawlvWlYlCsE5bdyffJiIMZZD9UrI7JrL1YzqoI-P2qM9yWct5PCQecLtVk6oCP7m%5FkKYybj7KE7NObHH6hzFF0k46%5FJbIOQGHEK-hCQIKqDbeCCD5xzu0d0LiSNvpn1cq-86b1V687OXmC60IFLyFiv1bhR6UX4CE1q56vhyrJipB4zFe7GpjaIzZHqNmi163PrATUvLNfQxM=?ref=biostockinfo.com) · [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHh%5FM78uDORInt51DZEkMU-APdWLdcVRgtU-zoamtcuh92CflFJEDiapc0eYKF-X8YRsCQs7btQQxPu2CNcLWyXrjCq5Wy4bmdXe8vmMSbl2iOH-9-b9L6cCuWU%5FA7VU5%5F-aFfZBlM4OEs7Voxl?ref=biostockinfo.com) · [ophthalmology360.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFBlkXnXAOyEseLXfx%5FjBg%5F7KHy5HUJQL6tDfmtfxKYDDsqo-hgsmb75wjewjA-0e1qNmAmZbDS%5FVVc1f0JwmcCxR4FLpRgKVdDjVv0sJ1IZxo2QArAHJhARrekEeurDX1CBEcfilmVXDmN9skfEwYWYVsvEYnbUhPnDAZu7aE6Z92zPUyJI3sFBwydgfvnJ%5F0VbTyMMmwe0-dM0-FhfOS-bzKKbKG6vFQ=?ref=biostockinfo.com)

**Why it could work.** Its pupil-constriction mechanism offers an alternative approach to near-vision correction. Whether this produces a useful efficacy and tolerability profile depends on the clinical evidence and eventual label.

**Why it could fail.** Approval is uncertain, and a crowded presbyopia market makes tolerability, convenience and uptake important commercial questions. The agency’s decision and label will define the next steps.

**Recent development.** On September 9, 2026, Opus announced preliminary Phase 1/2 results for its separate subretinal gene therapy OPGx-BEST1 showing visual and structural improvements ([opusgtx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxXB8u5MPOqYl9rsOgYTllAAHcsZEBZW4axL6HGHud9VkyD0c8fNLcGfPevEwS8lm9n6hPOn4RieIO90925jpwQu-rs6ryS-fIES-A0gujUYm%5F5N5dnhSaCZNroBKXpjqoK2jhTcvrhO6hTLsSIb1t37N2VuOZujlSilH3ICQX149pIpZKnRuWCM0QSVewoW2SFJ3yqYuQ0EVScrJUi-gnEWty2W7y1MvhV%5Fl6AoP2vx1aIB-4j0JihElls1%5F-XZ7BdUwnraqm%5FX44BEpvXcIjiWG7gq2iKqldTsy2QLgCLldIWBBKArjFa%5F4MFj6IWLvXsUQ4nc26B%5F2v6c8TFiuOSAilwv-37sJa0lSD8KNZoqLjfKpDCg==?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IRD&ref=biostockinfo.com)

### IONS — Ionis Pharmaceuticals

| CATALYST**Oct 26, 2026**Regulatory | RANK**81**           | PRICE**$44.50**\-29% 20d |
| ---------------------------------- | -------------------- | ------------------------ |
| CAP**$7.4B**(166M sh)              | CASH**$2.0B**\~48 mo |                          |

Priority Review

**The FDA rules on the Priority Review application for bepirovirsen in chronic hepatitis B on Oct 26, 2026: Priority Review.** The decision concerns bepirovirsen, which GSK is developing for chronic hepatitis B.

**Company.** Ionis Pharmaceuticals invents RNA-targeted therapeutics for serious cardiovascular, metabolic, and rare illnesses. It markets commercial therapies and partners with Roche, Novartis, and AstraZeneca. Pipeline candidates include sefaxersen and zilganersen.

**Science & competition.** Bepirovirsen is an antisense medicine developed for chronic hepatitis B. Rivals include Tenofovir alafenamide (Gilead Sciences, FDA-approved) and Entecavir (Bristol Myers Squibb, FDA-approved). Standard care includes oral antiviral treatment. This catalyst is separate from Ionis’s sefaxersen programme in kidney disease.

Competition sources

Sources: [uw.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFMGTasGsEA0TnBvGvsiG7hCnAxyNmYOfvmYhm%5F5ZYQ2p5fEWpgzFUqErDzyiTRIkTP5d9n2XZiR2wekkOBQA7mK%5FUSt7tXpeR0FPhb9adp3igVIDDC%5Fkk4kivBAapI4ESw86K0g66aO8TvangkVtnYVY86hYQBkv3KBj9jXA==?ref=biostockinfo.com) · [hepb.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRkBtcMY%5FJvnBx81M56nCT-nU2rFbUKbv-gxN9zi41uzOE7XaCr0sWslFDKS4Ysx4sUA6McjBQJQ0DgBTzSyNhAxX7GGVeSYbcp8c8KKTrwhoyHnEPTPiC6Vrum9LSJyWYMQTE3d6L3NX0WLFlgnxSmGF4J7-gy5IMRlk47eORfVxdR4NagaMlUyGp-mc=?ref=biostockinfo.com) · [pharmacytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGV5veYR82SKIZrOQVzctZYdg12feOzOIkOUm0IkNTtsKOR8LBfP%5F6%5FOnv87TcmMNcRBJAL7vi2dhg%5F0TA47VNU72-SFmMMv7LxNKzIenhUqq8pOk5RITu6kOc6hdQbwofrmsFsm3kr6U0dvO-J7oONiPB1p-v98X9NFs83CkibQUviMctrmUFGGJO9oaVx2oN%5FltlN%5FpsXdSxQ1aXXavg4YA==?ref=biostockinfo.com) · [insightaceanalytic.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF5BakUb9X2L4UeFBNtj3q8Eu-kl9vHke-76SuVPgx4Wzc2lAfUi6qL5AipJtmr%5Fa8OiHGz5-R1F%5FkHd0FRJHu6PK2-1%5FI4vTHWO3yEBdz8aq3c2xcqDXFXJFdTSWGWO7vYnyPs17hBjW3dkmkFhyj4EyzVBaBTvcj6f18e404Z-CHYFfXx9yLzLw==?ref=biostockinfo.com) · [pharmavoice.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGS1FY8HdQyamuU2n9-3944IMzS1Z5EK4iJiAm-joYBM0f63ruVL1ja%5F4X9tTaOSMgDUJc1ebl69gTyzEKEK40ljRYrD9qcB2r8av084S2pbAGQxVM7a4AtUlQLTig7SUrVEgoWTiijxQOYW1dfNHCFJMK3jW%5FZASDA72opSVQQwQ1u4ADKZ3n6IP9RTo8w014FgzsETA==?ref=biostockinfo.com) · [ajmc.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNqq3XED4xlBubtyYw6Nt2rCh6mL9%5F1LGhsxo7rDWxdEmkkJb7xcelB0BAYWgHp%5Fkou9n7m2e%5F-Ge2jv%5FGvz7wc%5FaS0a7N2H48yRLTZpqruphg7VEjSjsyKfsmg-Zbx71XwU4lhqjj4GfS8wxLxmi5FjYtE%5FPFETqBa03g%5FYCXT35bWrN4035iWStkkx%5FTkzpIJGg%5FxuU5XQM5Flw-JOWtAf6IjLzOASA3%5FCzrPmypPINvPg==?ref=biostockinfo.com) · [decibio.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG2o1jwLf5MkxMmXHkElY74KxT4o0vEIOAcQpshas9LT2BIcU9myIO1wcaaLZM6cei-m1UZsUPTOJhw8AbS2GbWowhwNJjQnlZsQ8pppRQeQOzxYtxqA1RxOtuI0GGW11DLVO3SK1ZgWr-YTtIQByQ29ENOsEjiuEuaMXK2hhMY2-Hr7GamA140OO0=?ref=biostockinfo.com) · [xtalks.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjqQ92L3XbphsA2gpQCxYWNF3ONJY0yRDfGyHfiVh%5FmsPiYM8nynCoT0G3pi%5FWyWUBN8oyYXNEC-UfrS--gEvitoVj0gqVg2dPq-v0VB%5FNtyWcyI3dgBk37%5FBC5TaRYjFvZXqQ1iHSumpXa8tcNp9yeBKX4UUFn%5FKoDg-uN6WW2-aAldVDEDmqeIHWvazoFX0aop0=?ref=biostockinfo.com)

**Why it could work.** Ionis reported positive Phase 3 B-Well data presented at EASL 2026\. The FDA granted Priority Review, and GSK leads development and commercialization ([company release](https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953%5Fex99-1.htm?ref=biostockinfo.com)).

**Why it could fail.** Approval and the eventual label remain uncertain. Ionis also depends on GSK’s regulatory and commercial execution under their collaboration ([company filing](https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm?ref=biostockinfo.com)).

**Recent development.** On September 3, 2026, the FDA approved Ionis's separate neurology drug ZANVASTRO (zilganersen) for Alexander disease and granted a Priority Review Voucher ([ionis.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8kicKy--elBYJAIIrw2B5%5Fc8m9jRjsc5NEPAq2LXvtioRUYa9NafCaWPlf2jHJttC%5Fv0uI85fLXzOWGDoJ%5FHCp81T6F9icIbrQziYQ5uYs66EaqwmyntAH2UEjnPGc5z4zIacWBCVrvRTREBYfKbyQPJTSmbjju94KHicr%5F2GbNo2ZlXqNogEBPMwMiynnQKHrUJPoMOyBp0tfMsxVCVEg-lBloldez6T9Xv8ICw=?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=IONS&ref=biostockinfo.com)

### RAPP — Rapport Therapeutics

| CATALYST**October 2026**Data readout | RANK**80**           | PRICE**$33.91**\-33% 20d |
| ------------------------------------ | -------------------- | ------------------------ |
| CAP**$1.6B**(48M sh)                 | CASH**$413M**\~51 mo |                          |

**Rapport Therapeutics reports topline results from the Phase 2 trial of RAP-219 in bipolar mania in October 2026 (company's words; month-level precision).** The data readout determines whether the company can expand its neuro-psychiatric pipeline beyond focal epilepsy.

**Company.** Rapport Therapeutics is a clinical-stage biotechnology company developing small molecules for neurological and psychiatric diseases. It generates no commercial revenue. The pipeline includes RAP-219 in focal onset seizures and primary generalized tonic-clonic seizures.

**Science & competition.** RAP-219 is an oral negative allosteric modulator that selectively targets AMPA receptors bound to transmembrane AMPA receptor regulatory protein gamma-8 to dampen neuronal hyperexcitability. Rivals include Lithium (Multiple, FDA-approved), Divalproex sodium / Valproate (AbbVie, FDA-approved), Carbamazepine extended-release (Validus Pharmaceuticals, FDA-approved), Chlorpromazine (Generic, FDA-approved), Olanzapine (Eli Lilly, FDA-approved), and Risperidone (Janssen / Johnson & Johnson, FDA-approved). Standard of care combines mood stabilizers with atypical antipsychotics.

Competition sources

Sources: [thepharmaletter.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHfZIMOTvzi7ce0cp4iNfsvAPrVPAjSkHnz4S5SZCRrVUSdU2SGC2E%5FmvpuZbm9U8-zsnH-JYMZcFrLjsxTSFqYEzm6U7-fOngPiXhjBLr4fe75tDIw1ERWllqh7nIG6qlvRfH7sR%5FtEaEkc2TJwfleOIHdBAi3J3QjxH5H97SJ9M82jlD5K4iV6spwVDkrdJUYU6DdqORg1sWGO0r3f3MpGgKPEjU9ZWj9-7x6uw==?ref=biostockinfo.com) · [morningstar.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9PU1uFniN0iy-niyYabTXZMjjQ3zxsZTNvLueUWIZ0QAzEoGp7sX%5FpWw2Fkm5CcXUJoMUfQiILf8%5FSmTgrorF8fJymRH0Lng-YuyGwg-xv%5FciWiQA226N4iDevVJ7PZV%5Fo1trvXOPqAKwmsAMmuvItTYi8E-Mwrm%5F0Ned0gUG-SPn4jbjOjdnRWUQPC9sGR3oVr8V6ylf%5FGVlrJi6ZMWtCEBanu7kOgNHz5TAhPBDQg6IOL09tzvGBp8jcvO3cBcJlQEMWqJrLpXpnyqJAkTyADPYSNzVyAAPLfMEnIkL?ref=biostockinfo.com) · [allsci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZ4PKQ4%5FezGUWUJzWK3Y04ZO6skCYPd22EJVj3ifX6Go4GrwuDnlKMnsGt%5FRwlQJTlrARbaMxknoMfC8KZKYI4MU%5FrKcR9xswiKctpmGND3ZBuY4Um0UOocu3jUfxPggavcBGLMM0gcYx-JmaLZNcuOE8yaapFn4GSg%5FUdznvFpNDWVCgwHXyGc6pXN2tKcJ0=?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3XUFGd%5FmQrzoTAMfg6bWQnSC%5FSnAgsG9zNlVA0pOy2mGTAudfUUUCgx7wjiur1fpYRHzt3j3pEi6GQd%5FaoqNdWwx7Vxv6sRDNhgLFmXEEC%5F3atb5CmiCQqwOuyvIHRxsYs3EUpgjJ?ref=biostockinfo.com) · [withpower.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGM9G2YZCZlQqGF8Ifxwvu4cWPaC0878OaWOS6-DzzKjw1Uu71oV5LEyMq3-FvQ9ZwE4OFsug2OR1gvlr1rkFxMeMXv-Di2G0StvSqgwGAKyS0wunhhcmzufRjkHPX2xyq2sjgXvvGG-nvUm1%5F9twrBnhW-tDw=?ref=biostockinfo.com) · [wikipedia.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFtxn4t2r-mYS4n5-pLiWOPO3pbw-oIhbJRo4q4-Kepu6dhljx7qC4MY9o1aWlzK5NkBgW-bHvuR8PQUaDc183B2JoUDJ1KhqNdmosK%5FnRqQ2f0SPtfHAbvzCcgfoZM-IPpckPre2g=?ref=biostockinfo.com)

**Why it could work.** The company reported encouraging seizure reductions in an open-label epilepsy study. Those findings support further study of RAP-219, but do not establish efficacy in bipolar mania.

**Why it could fail.** Mood trials suffer from high placebo response rates. If symptom reductions on the Young Mania Rating Scale do not separate statistically from placebo, psychiatric expansion plans will stall.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=RAPP&ref=biostockinfo.com)

### BNTC — Benitec Biopharma

| CATALYST**Oct 27–Oct 30, 2026**Conference | RANK**80**            | PRICE**$9.59**\-24% 20d |
| ----------------------------------------- | --------------------- | ----------------------- |
| CAP**$334M**(35M sh)                      | CASH**$175M**\~106 mo |                         |

ODD FTD

**Benitec Biopharma presents updated interim Phase 1b/2a data for BB-301 in oculopharyngeal muscular dystrophy-related dysphagia at the ESGCT Annual Congress between Oct 27–Oct 30, 2026.** The update should add information on swallowing outcomes and durability ahead of planned pivotal development.

**Company.** Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using DNA-directed RNA interference. It has no approved commercial products and focuses clinical development primarily on BB-301.

**Science & competition.** BB-301 uses a genetic vector to silence the disease-associated protein and supply a functional replacement. It is delivered locally to swallowing muscles. Standard care includes swallowing support, dietary changes and selected procedures. The research did not establish a separate competing clinical programme.

Competition sources

Sources: [firstwordpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFe6IE3zvSUPmWzd7cx1ekc%5FP5uPp-CW9qQvmU97QhpEP0yqdRYWysmgMnZXxqkbdCDYbgMVAXSnq0Cyt6rkZG-7og8vTNuHpSocJPu8xgYFSsc2clYO2fIYohxYMadbaBgCjl7?ref=biostockinfo.com) · [mdaconference.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQETJUtECRAvWfGGNebhpg%5FItPH9WfwclXSz0DJwRXRBRZlbprlC9WnS9hmRAPrX0EC7ewS4ILhNEhWglGpLoJBxDJgY9cISG3B1YnTb9CiEA1q45CornZFQMc-W-euyrRXo5jH0WKSPiXdM15MVbnkcMl74PnAhFd3fRgXbKOVlNlPndr7iAV5xoKvdgKPihQs%5FMmxXmsGTJTowAlttVYMe4UPemhiPpNcWpem0lCvXF9wZmfsyrNI%5F5jQApoGCcltpTiL46QJI%5F8DGOn3bWmy1EtkQhQx9eSDqbcsH9AFiANKKbvM9VdWqn-0YeDgxpdYoJ0bwP%5FXo4xPfziBHjX6D?ref=biostockinfo.com) · [cgtlive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZ0FlTTGMNOmde35y7vUqmkmkE6d3rvpMF-6pRn3athf3ogDhygHeJj4Sgp9KgmWmK2senxcJHX9Qbgw6LBOjU2vD5QsEXMksRBp4I8nxdBM3myixxa2kE9-cnxrXnTabsWiy7WLx9Ug0y0xEIgGCBFAPMD4YXN7XW%5F8g=?ref=biostockinfo.com) · [cloudfront.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEHxlz%5Fx8hopOAIbyS3ayGOZBPSoheypuLOEYaWbbfgCJMLf39HZouJXrXkWF9zSRKcx5VNNpAYbuLOBP39uViAXXTMnCGKCWt70maDPOajySiXeOd3DJ4cEL4OtbkvkSPPsD0Yo4QabGIiWRzAl2sEE6mW8CbL8ECsKnDv6ae2Po8Izo9KKeCxozIwx7PIHKhD6jVtz2rhZHmHB6%5FmjMkcbPyLgwm8RFsqiHx5dJeSqAqSpjkQw5m48JYGoFskQO330znO-Dh39EKKgDsG?ref=biostockinfo.com) · [mda.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZTX4nY%5F7zX3niq%5FVRMrrXEoMoWwa1Zcr5EpdoaK1I7svJCIA7acY13NIZvVRtl9dpUgLJJTlw9WLGTrsc72GOIz7giREDTTlzsPTNmUn8Nv1mEA4cxVkHSLXMgoSy1VsMdSf7wXzwsjch5Gdcxaxjw15TRXMCHg6UIeaoU2I=?ref=biostockinfo.com) · [nyulangone.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFeHAIEkkYv-i%5F2nATc7HDPKeHpCcVO8PdcI-uTXEY0L069XGAc4zAaiW03%5F%5F7Iub0gpLWl1hny0FtdpUmbdZGyg27jopY-IgcXv61I2WDAHOSMtXDp44T2lNj-R1Hql1Pl5Qs95nBmRORmK638D0SR%5FPjtUyYLCGdaIJmL7VdfX6EicZAWPrQidNOrLtzokCHvja8T6fq76ri3rrjIsAr0qo-hCf1mXKlzVqKYpA==?ref=biostockinfo.com)

**Why it could work.** The company has reported functional responses extending to 12 and 24 months in low-dose patients. Additional follow-up can help assess durability, while the high-dose cohort informs further development.

**Why it could fail.** The reported evidence comes from small cohorts, limiting conclusions about efficacy, durability and safety. Swallowing endpoints and the local delivery procedure will need careful assessment in larger studies.

**Recent development.** On September 14, 2026, Benitec reported that all six patients in Cohort 1 completed 12-month follow-up and Cohort 2 completed enrollment ([globenewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEc2aCpFdBdK5ZRGlWGz7a%5F%5FwmH8vkR-1KuVbsudwUXTWVT184qvdD0slSBhxFpfEURytCH9Cm1JQxqkUk5I0xreEy0hxpPQfkMOWANkQdbIJ2RIC4CJBLxRyFYkm3UoxC3YMtuAkI9Tsq3pqS8h%5FEUiemCqRy1cpx2ezPn4Tf-LLhW94iwOErbENRQVOvPWfU89Aa3-0G0RX0JW0IldcoiuV3FdVVVaWSDVvwQhz-TkVQ29aKd7bQeS5WWTAwyhsnmsQyPxdsuvBRDqw9o3wfZjoAePXh9%5Fd-C4XKFvxU=?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=BNTC&ref=biostockinfo.com)

### INO — Inovio Pharmaceuticals

| CATALYST**Oct 30, 2026**Regulatory | RANK**80**          | PRICE**$1.18**\-6% 20d |
| ---------------------------------- | ------------------- | ---------------------- |
| CAP**$122M**(103M sh)              | CASH**unavailable** |                        |

financing filed since the cash date Filing warning

**The FDA completes its Biologics License Application review for INO-3107 in adult recurrent respiratory papillomatosis on Oct 30, 2026.** The regulatory milestone determines whether the DNA medicine earns accelerated market approval.

**Company.** Inovio Pharmaceuticals is a biotechnology company developing DNA medicines for viral and oncology diseases. It has no approved commercial products. Other pipeline programs include partnered VGX-3100 for cervical dysplasia and preclinical hemophilia therapies.

**Science & competition.** INO-3107 is an antigen-encoding DNA plasmid designed to elicit targeted T-cell responses against human papillomavirus types 6 and 11 to stop airway papilloma recurrence. Rivals include Papzimeos (Precigen, FDA-approved). Standard of care relies on repetitive endoscopic surgical debulking and ablation of vocal cord lesions.

Competition sources

Sources: [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6JSEOILtiqCjKXQGkyMrqzHlKlqkk-GCezYuwiBD2wBqxN2JBJUC9GqZG2EUexP8Gds5D2vLwh5ahbHzxadM-9uOABPyTNoaG9NbWA5kSUnFLjIbI3n7HYouR%5FxLM7vxcwI8VJB-Sb7qh2b4JDNL6KFTduPmw%5FvPCAHuk%5FV22w3bX1Pyl-IbpQ3bN%5FJpSHDALXtjiNmUucsq0HzXiBIOqV2U3H5oY3Of3epG9I0lDX8RmCAU=?ref=biostockinfo.com) · [drugs.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIkoUsMO0FwNGKaVgnr4wwDPIunNG0rQfmPU%5FKDQd0AErnApQw3aWWvpCW97zgiMyVTexfPN5gGegE5Y82tY8sMhi5g1v8ldXpkXb5rFOm2Sli0jFp7a5HtHHKtuixQ9gLCTZF64YjocDMHGHgEwLW4mZ5D3vDfBuhKg==?ref=biostockinfo.com) · [ascopubs.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFsRuK0r4Mt9rzCGgjyO26FMa%5Fy6l5vtn8j%5FfMRysQw8zjC8Ptu1%5FV28VCk1DBYlYCeb-7xzsK9771AQQQRLgOUwvMsGiLV9O7KGlf5yQmff9xpu8u%5Fbq%5FvlubJQpmCyeK3F8q9B1xanTNt7syZ%5F0xpvh-hAyjFE1U=?ref=biostockinfo.com) · [primetherapeutics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYq%5FTTCw2vLBpIRWlUfu58jRpzSYMRr3Wl5n0CRCv0HtB6QVYBrQh%5F52FGRUAcFrFkQByiQQy0LVFbmrt3jOvf%5Fp25psEAKR1yCsc0zhDyLBtvpksCBRwOcwbDxoqW5KJOsVyB%5F5k06mIjYOfGMd6diAt8L4jyfFHIY193iw6Rbw==?ref=biostockinfo.com) · [springer.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEqolUbcVbimbvQdRhcqvJbA285AXBJIwErSnYaWUiGcjqVCOwAiVYw0cVpgukQDJhz-0m2BlkpS9kJNP1dS7ePnl5vaBtE1zFJVGD-PvS8-lHWEjFBSUxx%5FkJx1UgFgSXSVUAUK0F29wd4QfM=?ref=biostockinfo.com) · [withpower.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEtT%5FlMu%5FCWMGVybuk-KzxAxcXxe8cIa36izsohPfsaPU9wDjwfYPW%5FqaBbM5rUDrMyVuhHyARICymuUl8lUI%5FhQXvXYAOJwQmj57uGRmeoSoHfcVHEXzm2RxwSB%5FbDyINg4HBylutivgf-ed5hd7olyV5dlFqoFvdyHQ==?ref=biostockinfo.com) · [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHag9fYqWXflLKfhe3Z26Xwa7UghXqUCzubdg6uno41xIqbH0FASbTnkdw7Sg8vSGCWJ8MUouLwab%5FZxaiZ1-3kowD0TfwY%5FCEbcYcJ%5FWRWGvlsoFaSsTrxkteIFlwgwH2HoNhabZth?ref=biostockinfo.com) · [primetherapeutics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWkg8Y8z9DH4pb70086KxrLkq6rgD7pr4SorfQXpZqb9Ii1CvS53t2ODrPyf1mAkCC63ksfwKgK8c3fLRzrv5TCz%5FSYnnTxKa-wD7yB3mZY6rXebxrCFYguAdCXrqYWViFmCKU0oDGQ6JD8Ep6GNxKDy0inOXxS3aBKa4XAPafRQ==?ref=biostockinfo.com)

**Why it could work.** The BLA is under FDA review for a treatment intended to reduce recurrent airway disease. A positive decision would add a treatment option, but filing acceptance does not establish approvability.

**Why it could fail.** The FDA's initial file acceptance letter noted a preliminary conclusion that Inovio submitted inadequate evidence to support accelerated approval, creating significant risk of a Complete Response Letter.

**Filing flag.** In the file acceptance letter for the INO-3107 BLA, the FDA noted as a potential review issue its preliminary conclusion that the company has not submitted adequate information to support accelerated approval eligibility.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=INO&ref=biostockinfo.com)

### PALI — Palisade Bio

| CATALYST**Oct 17–Oct 20, 2026**Conference | RANK**80**           | PRICE**$1.45**\-31% 20d |
| ----------------------------------------- | -------------------- | ----------------------- |
| CAP**$253M**(174M sh)                     | CASH**$121M**\~80 mo |                         |

**Palisade Bio presents additional clinical data for PALI-2108 in inflammatory bowel disease at UEG Week between Oct 17–Oct 20, 2026.** The scientific presentation evaluates the gastrointestinal tolerability and mucosal response profile supporting Phase 2 development.

**Company.** Palisade Bio is a clinical-stage biopharmaceutical company developing colon-activated prodrugs for autoimmune and inflammatory diseases. It generates no commercial product revenue and focuses development on PALI-2108 across ulcerative colitis and Crohn's disease.

**Science & competition.** PALI-2108 is an oral prodrug that releases a phosphodiesterase-4 inhibitor locally in the colon with the aim of limiting systemic exposure. Rivals include Upadacitinib (AbbVie, Approved), Tofacitinib (Pfizer, Approved), Etrasimod (Pfizer, Approved), Ozanimod (Bristol Myers Squibb, Approved), Guselkumab (Johnson & Johnson, Approved), and Risankizumab (AbbVie, Approved). The standard of care begins with 5-aminosalicylates and corticosteroids before escalating to biologics.

Competition sources

Sources: [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFj69uR2dt4zPUgBiJt4zGoQSsrYax0oQJ-hIOBtoXuCveqR%5FBd6JL1cmYWne9bEZiyRBOiBMmJUjEV-I43xA6tUOEn7f47jGHc-%5FtgzMkzhLe8qT%5FEF284rC713e-LYsErz-Jnvua5lY1JAhGStpzeWSaC39z3a%5FErIwTPBxG3o0%5F8AkzgUHsl?ref=biostockinfo.com) · [marketbeat.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcLtjun2WXe3Zegq1XglvpGZIglTrJxfiMkFslEvVKa3juVsK0O1YcfjecxRKo3ntAAPKeV7GOQqawFLBlEN7zQWr0hVijTZDlCcned8WNmAS6-oA%5FafkcUiEHzQy-RGFN4kX9gQPmoV6G2Kyzm7rs2inu?ref=biostockinfo.com) · [forbion.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHgDus4d00nYjsV4pyqXMRrkgjJmPM2YXjLdG3TqRPQHKkl9hb81dCpb-iGUFs4oSZTDgBGmWizxoFTQczm%5FKW4q-BTVMxHUcXRfovSC2SHiNt2UTVYsCtnhFCQd4Trtj0RHSW3ingZg8EX1bmsoGSLV7E7H9FKsoJKu45FqYu-2z6%5FtiHMVUvkAndOTy2vzfjQfHNpZo6Akkrg1OKm6QhkbFxTQbRNJcJoHp8RhXST%5Fgq4DGFdm4JEiolnvQuvbkGoUztgbrG0AHZFK3slkqd%5FHeE%5FnrxJwlh0?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEc49N-NGDXCZg135PWrlCW%5F0q963ZXSn0m%5FihF1nUkAbBJPy5y9llPoy55c%5Fs3NAwv0BAT4GynbzaN8LV1rn4n9uZcpDshqjsHugZ76Wy-YE7Hnxbp3nxKFrbwFHLy1A2O6S1PQefMQ3dIBbpo8RW0YBHDXOs7UIL6xIfW%5Fip4bU4pDS-shg1iuJe5TQ==?ref=biostockinfo.com) · [abivax.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuG6OcAUUpVrDQ8F8lDhvdrSRLgaLRSfL-k-xHPgnNEpN3KZEhWfFYjFuO2hMCZFsrg8UR-8-lH-0GKqzmLyf2fYKMrsD1nbjh7wD8Lmb7MLwY3hQjgQSERIEi?ref=biostockinfo.com) · [jnj.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFmP8KJdaK5Ojzdad52fu-YL9MgCfY2zSjv6%5FZWlwj2OdsdgHKl2x0tFR7toQ3N4ozR-SlKtx-datRffQ-6KxgipdetMVNJr6jeJrOsSTQ94hYGKO1dXiRzfMJH1UHqdltp%5Fk2LXzBTmkVh11HzLsyCNDN5MwW9MAFplLNi7LwCf5P3?ref=biostockinfo.com) · [expertmarketresearch.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHpZpC3Lscs9UuvTxKtttfCWYS6K05o0k%5FeDzvR94DdZMiAXAoj%5FN4IJvdFi9X2-EEezgyJvFNCZuHiIKM1aCh29qxUdlwIrA3xaYJGMvDgHvVlmkNHuL4VQPEfzdCJ37vdSixh%5Furazjj%5F1cGPHREwc9Nl%5F%5FU1apLbyXaWJDPzNrB-tsVBSeYceOeyPcmCcbuCu4U=?ref=biostockinfo.com) · [inflectionlabs.bio](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4E56yAwAkwgww5AZ13S2bo7DFdPk1P0ZQT72bpWwKPGyrbsUP6-rUCT0NUv9yktTfAQNwvPgb2m4pkpLEeYqzPFjKFXi14C7sUdtpmSUItGphU5SJaU2GTAthcarGUHiDD2VtHgMNR1NVesPJ%5Ft4-rnfucfMnardKEFxHa%5FHXFA==?ref=biostockinfo.com)

**Why it could work.** In the small Phase 1 cohorts, five of five ulcerative colitis patients achieved clinical response and two of five Crohn’s patients achieved endoscopic remission. These early findings require confirmation in larger studies.

**Why it could fail.** Efficacy signals rest on an open-label cohort of ten total patients. Typical class-wide adverse events such as nausea could reappear in larger patient populations.

**Recent development.** On September 22, 2026, the FDA cleared Palisade Bio's Investigational New Drug application for PALI-2108 to begin the ASCENTRA-CD Phase 2 trial in Crohn's disease ([biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGC5p1Us72avQv8mX2ywryKLY4ZbRNoeIII-KInB0wTyePRe3OU8CSVEmnJaznwxBi-td8SKj5ZVeMWU6gfn-PRCzqOLjtg%5ForR5OjhoPVERFzN0BuQcAb1u-7NjYMdCrA4pWSO5EaLYuLicI9PJKiNnYhI-7VNSBOLEbitC1JWcRwWLq9C36tF9MuSDpRIXdTVb-zENTt3m1xusfR4V9UIyS3mUXXSuMAorKfCvF%5F4fTd2iXC0-pZttd-OncX-hIw20rLN2xRUNSK3m4aIR-oK%5FGK7Sc70DQ==?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=PALI&ref=biostockinfo.com)

### BMEA — Biomea Fusion

| CATALYST**October 2026**Data readout | RANK**79**         | PRICE**$1.32**\-21% 20d |
| ------------------------------------ | ------------------ | ----------------------- |
| CAP**$96M**(72M sh)                  | CASH**$24M**\~6 mo |                         |

financing filed since the cash date

**Biomea Fusion reports initial 28-day clinical weight reduction results from the Phase 1 GLP-131 trial of BMF-650 in October 2026 (company's words; month-level precision).** The readout determines whether the small molecule can establish clinical credibility in oral weight management.

**Company.** Biomea Fusion is a clinical-stage diabetes and obesity company. It generates no product revenue. Lead programs include icovamenib in Phase 2 for type 1 and type 2 diabetes, alongside BMF-650.

**Science & competition.** BMF-650 is an oral small-molecule glucagon-like peptide-1 receptor agonist intended to promote satiety without requiring subcutaneous administration. Rivals include Semaglutide (Novo Nordisk, Approved), Tirzepatide (Eli Lilly, Approved), Orforglipron (Eli Lilly, Approved), Liraglutide (Novo Nordisk, Approved), Phentermine / Topiramate (VIVUS, Approved), and Naltrexone / Bupropion (Currax Pharmaceuticals, Approved). Standard of care relies on once-weekly subcutaneous incretin injectables alongside lifestyle interventions.

Competition sources

Sources: [biomeafusion.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9wIob8pTl5r8P8RVwKwjDEYPnF7OLGRRhCqVPCmovfbl-BI%5FM9d4T4Fi73IHonGDZb%5FTI1yiIPngyesmwXrzu3S40nr9R--bYt9ep8j2FBb-lQ026e%5FXP-3SE00q5GRqthnBu3%5FuqSHWFxkKUktOU1yvo-Ao0OjedXUvgQji6iujv8zmGUT39imWJ7w9a%5F3Jg%5FJFv0w3DD5esFMkx6wzZfFmpIRyKQ8AlvSxsYtUOvF9qSPi%5F6EiRGrU=?ref=biostockinfo.com) · [pharmacytimes.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEFT0DI%5FqHAWgLm3S2AXtS3iCuGtyAskTRWT5R3bvS5FejQ91wkPVkzlDxhT0wiJeR21eMOV6kvjK114rVBLGObQiahJkKI3eVEcruKwsT24nusEJxDKRA2Ci8C38aR7h--b4FCrZKT1cbAkEJKgqjsSJ3SoHMY1Zg7eJRIlAL-6H0h38fX55ntNlE=?ref=biostockinfo.com) · [ozmosi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFNeHQ-KmUidXHaazUqtGvqI9KywO4buwuAFEE%5FesXI3eD9MrNMkOIjcuxqsAeOOOYsASIY4MkbN%5FHSJErLxw-UIlnU96JIq5gGWZTGbjfzWUQizwbMlxUCkAOlTd99GU3gKRcM2opU0A==?ref=biostockinfo.com) · [eurekalert.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbgGmyXw-dgAcfZAkuhT6ilGFO1GkXtxHQhLdo-rRJJChlyY9r3FH-qQwU4MQrrzSPavNIPKaywwnpFpmEeQnUUajtjdEJjHbvDccE0rCwRQzUvGD%5FkBPWMcVgyYdkg%5FAeJGoWNd5SNHq%5F9w==?ref=biostockinfo.com) · [beckershospitalreview.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE%5FUhvPH3gTkMnJMbVa9ZjbiD92n%5FQwL2jSIRUYeDTVJZvEpaaobD4LpUHt%5FUINVvAlO8jm9DYoYouQR2yJiJxhYTnuoQhb-mR0rO9LjBxfFPdnRGrwgEPQo91vwot13tqd1f-jZAUS9%5FPakncDe4w2VAlXwE6CG9nSD3rY-jgq1PSNlX3PgqUcxhisJt4xyM-kDvtSThT-KsdOoaIcCpyeeO4=?ref=biostockinfo.com) · [iqvia.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOXnzYahvc8HFlrLjdT%5FwwEDPVGQMwyhbCJioHMJ1AwAQsHrOI%5FOLU1421FP-wn1gRaEpb%5Fri0FLycemBceuuQ3h7y5bh9%5FI7xam9t674kD3i%5FFx4c6jLtp7eJHDazns6QsNKZH3kk0dh6WU5MGLcoc9H3AD2z4l0ZcusLHX3a2iWu86LBKlo79A==?ref=biostockinfo.com) · [delveinsight.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEuZ3ouPdaTYISRGTt%5FfgEAdfMPqRItXv81RzGkSMNsTB6SB4fzr%5F2qK0s8pm7t-lygXnQI0rg%5FjYMaE9kUKIB1RXhDDq8tyUvMMoJrKHyUp69ratpukOLaNy6l15t2N-faiyfx-Ms0HrEDgjz5vpatE5808-A8iKiSwfu8YQvfu2miJQUxHYRM-DqF81lAaOXdZzSYuBT11hkilQdxKw==?ref=biostockinfo.com) · [lifesciencedaily.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfKKIoH2QSXJwWLK8-DWX9kJQR9-CvoasnP3d9FG-qRrXvN3YjOV4VqCduAkbMfD6DYJBIcd6EC1J1tQ8UtFNKxuRd-l6P2mRqC9b6k1uVDRJepF9E-We8PdP8FvYgjlVr6wEYdSC7hswwzBMfyERKSRk=?ref=biostockinfo.com)

**Why it could work.** The trial evaluates a rapid one-step titration design, which could bypass lengthy multi-week dose-escalation periods if early weight loss matches peer benchmarks.

**Why it could fail.** Rapid dose escalation could produce gastrointestinal adverse effects or discontinuations. The small early trial must establish interpretable safety and weight-loss results; a promising early signal would still require larger studies.

**Recent development.** On September 23, 2026, Biomea Fusion terminated its planned underwritten public offering of common stock and pre-funded warrants due to market conditions ([globenewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFWBNqI2zoa53azs3iTfBoHjH-WtIVqVH0I6cfC6CBksx1ahCmplH13Bfrf92tRvGQ%5F0KQ8AG8qzMu5nh08J9I0Y13bbbAqVfdXYX0tkBy-JLhz5iYEiYk-bSQB3yQbmWvj1qCL-KWnNN3IgAeLDuyOAS90Jcg3ABqMTEFFmbBTgjdUJMXjLRaM72OKtOC2xV5BMGNa-d%5FTKBArBBGZOWs-3vlzz0kzYu2Iae78-yY91wNu4-W-reLFJc0LeyC0AKILTuFMvPUJZrxFIzXc2SINg==?ref=biostockinfo.com)).

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=BMEA&ref=biostockinfo.com)

## Watchlist

### MGNX — MacroGenics

| CATALYST**Oct 26, 2026**Conference | RANK**79**           |
| ---------------------------------- | -------------------- |
| PRICE**$3.74**\-8% 20d             | CAP**$238M**(64M sh) |

Cash $221M, \~42 mo

Filing warning

MacroGenics presents interim Phase 2 LINNET data for lorigerlimab in advanced gynecologic cancers at ESMO on Oct 26, 2026\. A clear response rate is critical because the company discontinued the platinum-resistant ovarian cancer arm after it missed target efficacy thresholds. In 16 evaluable patients with clear cell gynecologic cancer, lorigerlimab demonstrated a 25% objective response rate, though grade 3 or higher treatment-related adverse events occurred in 47% of patients.

**Filing flag.** The predetermined response rate was not achieved in the high-grade serous and platinum-resistant ovarian cancer (PROC) cohort of the LINNET study, leading the company to discontinue development in that indication.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=MGNX&ref=biostockinfo.com)

### NKTX — Nkarta

| CATALYST**Nov 8, 2026**Conference | RANK**79**           |
| --------------------------------- | -------------------- |
| PRICE**$2.75**+0% 20d             | CAP**$197M**(72M sh) |

Cash $221M, \~29 mo

Nkarta presents preliminary Phase 1/2 clinical and safety data for allogeneic CAR natural killer cell therapy NKX019 in idiopathic inflammatory myopathy at ACR Convergence on Nov 8, 2026\. The readout provides a key clinical proof-of-concept milestone for off-the-shelf cell therapy in autoimmune disease. Prior data showed deep B-cell depletion in all lupus nephritis patients treated with fludarabine and cyclophosphamide conditioning.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=NKTX&ref=biostockinfo.com)

### AKBA — Akebia Therapeutics

| CATALYST**in Q4 2026**Data readout | RANK**78**            |
| ---------------------------------- | --------------------- |
| PRICE**$0.90**\-5% 20d             | CAP**$248M**(277M sh) |

Cash $156M, no net burn

Filing warning

Akebia expects topline data from the Phase 3b VOCAL trial evaluating three-times-weekly dosing of Vafseo versus standard erythropoiesis-stimulating agents in Q4 2026 (company's words; quarter-level precision). In the 2,116-patient VOICE trial, Vafseo demonstrated improved safety outcomes over erythropoiesis-stimulating agents on a composite of mortality and hospitalization. Second-quarter net loss stood at $8.9 million, reflecting a restructuring charge.

**Filing flag.** Net loss was $8.9 million in the second quarter of 2026 compared to net income of $0.2 million in the second quarter of 2025, driven by lower revenues and higher expenses, including a $1.9 million restructuring expense.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=AKBA&ref=biostockinfo.com)

### CLDX — Celldex Therapeutics

| CATALYST**late 2026**Data readout | RANK**78**           |
| --------------------------------- | -------------------- |
| PRICE**$31.10**\-23% 20d          | CAP**$2.4B**(78M sh) |

Cash $660M, \~34 mo

Celldex expects Phase 2 topline data for barzolvolimab in moderate-to-severe atopic dermatitis in late 2026 (company's words; quarter-level precision). The company recently confirmed primary endpoint success in two Phase 3 chronic spontaneous urticaria trials, supporting a planned 2027 Biologics License Application. Earlier this year, barzolvolimab missed primary endpoints in a Phase 2 prurigo nodularis study.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CLDX&ref=biostockinfo.com)

### FTH — Faeth Therapeutics

| CATALYST**year-end 2026**Data readout | RANK**78**           |
| ------------------------------------- | -------------------- |
| PRICE**$28.00**\-17% 20d              | CAP**$724M**(26M sh) |

Cash $178M, \~63 mo

Faeth Therapeutics plans to report topline results from the Phase 2 FTH-PIK-201 trial of PIKTOR in second-line advanced endometrial cancer by year-end 2026 (company's words; quarter-level precision). Earlier studies cited by the company reported activity in gynecologic cancers; this Phase 2 readout must establish the programme’s results in the selected population. The company completed a reverse merger and private placement earlier this year to support operations through the readout.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=FTH&ref=biostockinfo.com)

### CRVS — Corvus Pharmaceuticals

| CATALYST**late this year**Data readout | RANK**78**           |
| -------------------------------------- | -------------------- |
| PRICE**$11.62**\-21% 20d               | CAP**$978M**(84M sh) |

Cash $204M, \~55 mo

Corvus expects results from cohort 1 of the Phase 1b/2 trial of oral ITK inhibitor soquelitinib in atopic dermatitis late this year (company's words; quarter-level precision). In an earlier Phase 1 cohort, 75% of patients achieved an EASI 75 response after 56 days of treatment without rebound symptoms. The compound is also undergoing registrational Phase 3 testing in peripheral T-cell lymphoma.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CRVS&ref=biostockinfo.com)

### DTIL — Precision BioSciences

| CATALYST**by year-end 2026**Data readout | RANK**78**           |
| ---------------------------------------- | -------------------- |
| PRICE**$6.22**\-26% 20d                  | CAP**$172M**(28M sh) |

Cash $100M, \~23 mo

RPD ODD FTD

Precision BioSciences plans to report initial safety data from the Phase 1/2 FUNCTION-DMD trial evaluating gene-editing therapy PBGENE-DMD in Duchenne muscular dystrophy by year-end 2026 (company's words; quarter-level precision). The study recruited ambulatory boys ages 2 to 7 with mutations between exons 45 and 55, aiming to restore dystrophin expression. The company dosed the first patient in August 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=DTIL&ref=biostockinfo.com)

### CATX — Perspective Therapeutics

| CATALYST**Oct 23, 2026**Conference | RANK**78**            |
| ---------------------------------- | --------------------- |
| PRICE**$2.52**\-21% 20d            | CAP**$288M**(114M sh) |

Cash $214M, \~28 mo

Perspective Therapeutics delivers an oral presentation of updated Phase 1/2a data for lead radiopharmaceutical VMT-alpha-NET in neuroendocrine tumors at ESMO on Oct 23, 2026\. The trial treats somatostatin receptor type 2-positive patients across four cohorts, with 76 neuroendocrine tumor patients treated as of July 2026\. Phase 3 trial site activation remains targeted around year-end 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=CATX&ref=biostockinfo.com)

### OCS — Oculis Holding AG

| CATALYST**around year-end**Data readout | RANK**78**           |
| --------------------------------------- | -------------------- |
| PRICE**$9.27**\-25% 20d                 | CAP**$630M**(68M sh) |

Cash $45M, \~8 mo

Oculis expects topline results from the PREDICT-1 registrational trial of topical anti-TNF-alpha agent licaminlimab in dry eye disease around year-end (company's words; quarter-level precision). The trial employs a genotype-based precision strategy and had randomized over 45% of target patients by August. The company also acquired worldwide rights to neuroprotective candidate Privosegtor in August 2026.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=OCS&ref=biostockinfo.com)

### ADCT — ADC Therapeutics

| CATALYST**end of 2026**Data readout | RANK**77**            |
| ----------------------------------- | --------------------- |
| PRICE**$1.27**+13% 20d              | CAP**$162M**(128M sh) |

Cash $194M, \~23 mo

Filing warning

ADC Therapeutics anticipates full Phase 1b LOTIS-7 data evaluating ZYNLONTA with glofitamab in relapsed or refractory diffuse large B-cell lymphoma by the end of 2026 (company's words; quarter-level precision). Following an August pre-sBLA meeting, the FDA noted substantial concerns regarding the benefit-risk balance in the confirmatory LOTIS-5 trial due to an imbalance in Grade 5 fatal adverse events. The company completed enrollment of 100 patients in LOTIS-7 in June.

**Filing flag.** Following an August 2026 pre-sBLA meeting, the FDA noted substantial concerns regarding the benefit-risk or verification of clinical benefit observed in the LOTIS-5 trial based on an imbalance in Grade 5 events when assessed in the context of a marginal treatment benefit.

[Open company calendar →](https://app.biostockinfo.com/ticker.html?t=ADCT&ref=biostockinfo.com)

## The Take

The issue groups three different questions. Regulatory decisions at NRXP, AGIO, IRD, IONS and INO concern application review and potential labels. Conference presentations at KYTX, BNTC and PALI will expand the available clinical evidence; they are not approval decisions. RAPP and BMEA face new data readouts whose interpretation depends on study design, safety and the size of the observed effect. XBI’s weekly decline alongside SPY’s gain shows biotech underperformance, while the higher Treasury yield and weak broad-universe breadth provide additional context. Financing and regulatory qualifications remain material: BMEA has terminated a proposed offering, and INO has disclosed FDA concerns about accelerated-approval eligibility. These distinctions matter more than treating every calendar entry as an equivalent binary event. Scanner rank measures the configured research criteria; it does not establish approval probability, protection from dilution or a preferred investment.

*How the scanner ranks names, estimates cash and reads dates is explained in [the methodology note](https://www.biostockinfo.com/methodology/). Companies' own words and SEC filings are the only source for every date above; rivals are named from a cited web search. Not investment advice.*

## Disclaimer

For information and education only; not investment advice or a recommendation to buy or sell any security. This AI-assisted newsletter may contain errors or omissions, and catalyst dates can change. Verify details against original sources and do your own research. Biotechnology investing involves substantial risk, including loss of capital.